Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/21/2024 | Outperform → Mkt Perform | William Blair | |
| 11/8/2024 | $13.00 | Overweight | Stephens |
| 8/8/2024 | $10.00 | Buy | Stifel |
| 5/7/2024 | $10.00 | Buy | Jefferies |
| 2/9/2024 | $8.00 | Buy | BTIG Research |
| 1/23/2024 | $12.00 | Outperform | Leerink Partners |
| 9/5/2023 | $7.00 | Outperform | RBC Capital Mkts |
| 11/2/2021 | $16.00 | Neutral | B of A Securities |
- Preliminary data from the first-in-patient Phase 1 dose escalation trial of PYX-201 to be announced at upcoming virtual and in-person event in New York City on Wednesday, November 20, 2024, at 4:30 p.m. ET - Preliminary data from the Phase 1 trial of PYX-106 is expected to be reported by year-end 2024 - Expected cash runway into 2H 2026 BOSTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update. The Company ended the third quarter of 20
- Preliminary data from the Phase 1 trial of PYX-201 remains on track to be announced in the fall of 2024 - Preliminary data from the Phase 1 trial of PYX-106 is expected to be reported by year-end 2024 - Expected cash runway into 2H 2026 BOSTON, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update. The Company ended the second quarter of 2024 with $157.2 million in cash, cash equivalents, restricted cash and short-term investments, which is expected
PYX-201 Phase 1 trial clinical readout on track for fall of 2024 Executive Leadership Team expanded with the appointment of Stephen Worsley as Senior Vice President, Chief Business Officer PYX-106 Phase 1 trial clinical readout on track for 2H 2024 Expected cash runway into 2H 2026 BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update. PYX-201, a first-in-concept tumor stroma targeting antibody-drug conjugate (ADC) against the stromal Extradom
BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: "PYXS"), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effective June 10, 2024. Mr. Metzger has over 25 years of experience in the biopharmaceutical sector, currently serving as Chief Executive Officer and as a member of the Board of Directors of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) since 2015. "We are delighted to have Michael, a proven leader in our industry with a robust track record of success, join the board," said Lara S. Sullivan, M.D., President and Chief Ex
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: "PYXS"), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Santhosh Palani, Ph.D., CFA, to its board of directors, effective March 12, 2024. "We are thrilled to have Santhosh join the Pyxis Oncology board. Santhosh brings a wealth of business, investment, strategic, and board experience to our team," said Lara S. Sullivan, M.D., President and Chief Executive Officer of Pyxis Oncology. "Santhosh's guidance, drawing from his experience working across the biopharma industry, will be invaluable as we continue clinical devel
Dr. Gandhi is VP and Head of Strategic Partnerships for Pfizer Ignite and will bring clinical, strategic and financial leadership to biotech's board 1910 Genetics, the only biotech advancing small and large molecule drug discovery with an automated, multimodal AI platform, today announced the appointment of Shaan C. Gandhi, MD, DPhil, to its board of directors. Gandhi joins as an independent board director and will provide a critical clinical perspective alongside his extensive background in biotechnology investing and strategic collaboration at a time when 1910 Genetics continues to build pharmaceutical and technology partnerships and advance its own pipeline of AI-derived therapeutics.
SC 13G/A - Pyxis Oncology, Inc. (0001782223) (Subject)
SC 13G/A - Pyxis Oncology, Inc. (0001782223) (Subject)
SC 13D/A - Pyxis Oncology, Inc. (0001782223) (Subject)
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) with a Buy and maintains $7 price target.
Jefferies analyst Farzin Haque assumes Pyxis Oncology (NASDAQ:PYXS) with a Buy rating and announces Price Target of $10.
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) with a Buy and maintains $7 price target.
— PYX-201 achieved a confirmed 50% ORR by RECIST 1.1 including one Complete Response and 100% Disease Control Rate in six heavily pretreated HNSCC patients, supporting differentiated mono and front-line combo therapy expansion trials to begin dosing 1Q25 — Overall, 26% ORR across all six Solid Tumor Types of Interest (n=31) with Dose Dependent Responses Observed, Supporting First-In-Concept Mechanism with Novel Extracellular Targeting ADC — New Clinical Trial Collaboration Agreement with Merck (known as MSD outside of the US and Canada) to evaluate the combination of novel extracellular PYX-201 ADC and Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) to begin dosing 1Q25 in pat
- Preliminary data from the first-in-patient Phase 1 dose escalation trial of PYX-201 to be announced at upcoming virtual and in-person event in New York City on Wednesday, November 20, 2024, at 4:30 p.m. ET - Preliminary data from the Phase 1 trial of PYX-106 is expected to be reported by year-end 2024 - Expected cash runway into 2H 2026 BOSTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update. The Company ended the third quarter of 20
BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced that it will host an in-person and virtual investor event to discuss preliminary data from the ongoing Phase 1 clinical trial evaluating PYX-201 in multiple types of solid tumors. The event will be held on November 20, 2024, at 4:30 p.m. ET at Venue 42 by Convene, located at 5 Times Square in New York City. Virtual attendance is also available. Pyxis Oncology's executive management team will be joined by the following physician thought leaders to discuss preliminary data from the Phas
4 - Pyxis Oncology, Inc. (0001782223) (Issuer)
4 - Pyxis Oncology, Inc. (0001782223) (Issuer)
4 - Pyxis Oncology, Inc. (0001782223) (Issuer)
William Blair downgraded Pyxis Oncology from Outperform to Mkt Perform
Stephens initiated coverage of Pyxis Oncology with a rating of Overweight and set a new price target of $13.00
Stifel initiated coverage of Pyxis Oncology with a rating of Buy and set a new price target of $10.00
8-K - Pyxis Oncology, Inc. (0001782223) (Filer)
S-8 - Pyxis Oncology, Inc. (0001782223) (Filer)
8-K - Pyxis Oncology, Inc. (0001782223) (Filer)
4 - Pyxis Oncology, Inc. (0001782223) (Issuer)
3 - Pyxis Oncology, Inc. (0001782223) (Issuer)
4 - Pyxis Oncology, Inc. (0001782223) (Issuer)